as 10-29-2025 4:00pm EST
OptimizeRx Corp is engaged in the healthcare market in the United States. It provides digital health messaging via electronic health records, providing a direct channel for pharmaceutical companies to communicate with healthcare providers and patients. The cloud-based solution supports patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and clinical information. Its product offerings are Financial Messaging, Brand and Clinical Messaging, Brand Support, and Patient Engagement.
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | WALTHAM |
| Market Cap: | 380.6M | IPO Year: | N/A |
| Target Price: | $12.19 | AVG Volume (30 days): | 270.3K |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.54 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.78 - $22.25 | Next Earning Date: | 11-06-2025 |
| Revenue: | $104,748,000 | Revenue Growth: | 25.89% |
| Revenue Growth (this year): | 17.92% | Revenue Growth (next year): | 10.91% |
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Silvestro Stephen L | OPRX | Chief Executive Officer | Oct 3 '25 | Sell | $18.75 | 1,620 | $30,375.00 | 188,916 | |
| Spangler Patrick D | OPRX | Director | Aug 28 '25 | Sell | $17.49 | 11,120 | $194,488.80 | 44,215 |
OPRX Breaking Stock News: Dive into OPRX Ticker-Specific Updates for Smart Investing
Zacks
a month ago
GlobeNewswire
2 months ago
MT Newswires
2 months ago
GlobeNewswire
2 months ago
Simply Wall St.
2 months ago
Zacks
2 months ago
Zacks
4 months ago
GlobeNewswire
4 months ago
The information presented on this page, "OPRX OptimizeRx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.